{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:44Z","timestamp":1790812124013,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>Dyslipidemia has been frequently reported and associated with increased cardiovascular risk in patients with Cushing\u2019s disease (CD). Few studies are available regarding the relationships between lipid abnormalities and other preoperative metabolic comorbidities in CD, and the data on alterations of the lipid profile after surgery is quite variable. We aimed to investigate the associations between hyperlipidemia and other baseline metabolic and hormonal parameters and the impact of surgical remission on lipid metabolism in patients with CD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included 104 patients diagnosed with CD. Baseline hormonal and metabolic parameters were compared between the hyperlipidemia (HLP) group and non-hyperlipidemia (NLP) group, and their relationships with hyperlipidemia at diagnosis were evaluated. Alterations in lipid profiles after surgical remission of CD were evaluated in 65 patients with available follow-up data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Upon baseline, logistic regression analysis showed that impaired glucose metabolism (IGM) (OR=4.68, 95%CI:1.38\u201315.91) and morning cortisol levels (per 10 \u03bcg\/dl change) (OR=1.81, 95%CI:1.11\u20132.95) are both independent risk factors of preoperative occurrence of hyperlipidemia in patients with CD. The baseline triglyceride (TG) level was positively correlated with systolic blood pressure (SBP) (r=0.297, p=0.003). Lipid abnormalities had improvement but may persist after surgical remission, and the persisted hyperlipidemia is associated with higher baseline total cholesterol (TC) levels (r=0.505, p=0.033).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Persistence of post-surgery hyperlipidemia is associated with severe baseline lipid abnormalities. Surgical remission with concomitant control of impaired glucose metabolism at diagnosis may have significant implications for controlling hyperlipidemia and reducing cardiovascular risk in CD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2020.600323","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T05:26:43Z","timestamp":1612848403000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Lipid Abnormalities in Patients With Cushing\u2019s Disease and Its Relationship With Impaired Glucose Metabolism"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiaolin","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjie","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(16)00086-3","article-title":"Complications of Cushing\u2019s syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","article-title":"Complications of Cushing\u2019s disease - prospective evaluation and clinical characteristics. Do they affect the efficacy of surgical treatment","volume":"63","author":"Witek","year":"2012","journal-title":"Endokrynol Polska"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1530\/eje-15-0354","article-title":"Metabolic comorbidities in Cushing\u2019s syndrome","volume":"173","author":"Ferra\u00f9","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/bf03345431","article-title":"Advances in the epidemiology, pathogenesis, and management of Cushing\u2019s syndrome complications","volume":"35","author":"Arnaldi","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000314213","article-title":"Pathophysiology of dyslipidemia in Cushing\u2019s syndrome","author":"Arnaldi","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0370","article-title":"Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis","volume":"94","author":"Anagnostis","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1677\/joe-08-0054","article-title":"Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome","volume":"197","author":"Macfarlane","year":"2008","journal-title":"J Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/hco.0000000000000407","article-title":"Dyslipidaemia in type 2 diabetes mellitus: bad for the heart","volume":"32","author":"Katsiki","year":"2017","journal-title":"Curr Opin Cardiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ecl.2013.10.005","article-title":"Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism","volume":"43","author":"Geer","year":"2014","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing\u2019s Syndrome: An Endocrine Society Clinical Practice Guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The Treatment of Cushing\u2019s Disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocrine Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030871","article-title":"Diagnosis and complications of Cushing\u2019s syndrome: a consensus statement","volume":"88","author":"Arnaldi","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1365-2362.2008.02067.x","article-title":"Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options","volume":"39","author":"van Raalte","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000314294","article-title":"Management of dyslipidemia in Cushing\u2019s syndrome","author":"Greenman","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1297","article-title":"Changes in adenosine 5\u2019-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing\u2019s syndrome","volume":"93","author":"Kola","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2008.08.001","article-title":"The glucocorticoid receptor controls hepatic dyslipidemia through Hes1","volume":"8","author":"Lemke","year":"2008","journal-title":"Cell Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1066285","article-title":"A transgenic model of visceral obesity and the metabolic syndrome","volume":"294","author":"Masuzaki","year":"2001","journal-title":"Sci (N Y NY)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0305524101","article-title":"Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice","volume":"101","author":"Paterson","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/ec-18-0010","article-title":"Evaluation of lipid profile and its relationship with blood pressure in patients with Cushing\u2019s disease","volume":"7","author":"Qin","year":"2018","journal-title":"Endocrine Connections"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101380","article-title":"Cushing\u2019s syndrome: Overview of clinical presentation, diagnostic tools and complications","volume":"34","author":"Barbot","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-019-0438-0","article-title":"Lipoprotein particles in patients with pediatric Cushing disease and possible cardiovascular risks","volume":"86","author":"Makri","year":"2019","journal-title":"Pediatr Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04055.x","article-title":"Metabolic and cardiovascular outcomes in patients with Cushing\u2019s syndrome of different aetiologies during active disease and 1 year after remission","volume":"75","author":"Giordano","year":"2011","journal-title":"Clin Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02168.x","article-title":"High cardiovascular risk in patients with Cushing\u2019s syndrome according to 1999 WHO\/ISH guidelines","volume":"61","author":"Mancini","year":"2004","journal-title":"Clin Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1055\/a-0879-5122","article-title":"Pattern of Lipid Abnormalities Among South Asian Indians With Cushing\u2019s Syndrome and the Short Term Impact of Surgical Correction of Hypercortisolism","volume":"51","author":"Dhingra","year":"2019","journal-title":"Hormone Metab Res Hormon Und Stoffwechselforschung Hormones Metabol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2008.08.005","article-title":"Insulin resistance, inflammation, and non-alcoholic fatty liver disease","volume":"19","author":"Tilg","year":"2008","journal-title":"Trends Endocrinol Metabol: TEM"},{"key":"B26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mce.2007.05.015","article-title":"Glucocorticoids, metabolism and metabolic diseases","volume":"275","author":"Vegiopoulos","year":"2007","journal-title":"Mol Cell Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2337\/diab.31.3.217","article-title":"Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus","volume":"31","author":"Kissebah","year":"1982","journal-title":"Diabetes"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000172689.53992.25","article-title":"Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia","volume":"25","author":"Adiels","year":"2005","journal-title":"Arteriosclerosis Thrombosis Vasc Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0026-0495(96)90246-2","article-title":"Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study","volume":"45","author":"Siegel","year":"1996","journal-title":"Metabolism: Clin Exp"},{"key":"B30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.amjcard.2012.02.051","article-title":"Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution","volume":"110","author":"S\u00e1nchez-Quesada","year":"2012","journal-title":"Am J Cardiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2016.10.014","article-title":"Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c","volume":"1862","author":"Gomez Rosso","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/jci10762","article-title":"Insulin resistance and cardiovascular disease","volume":"106","author":"Ginsberg","year":"2000","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0524","article-title":"The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients","volume":"91","author":"Filipsson","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/art.21329","article-title":"Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey","volume":"53","author":"Choi","year":"2005","journal-title":"Arthritis Rheumatism"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-014-0232-0","article-title":"Lipid abnormalities in patients with adrenal incidentalomas: role of subclinical hypercortisolism and impaired glucose metabolism","volume":"38","author":"Masserini","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000314319","article-title":"Pathophysiology of diabetes mellitus in Cushing\u2019s syndrome","author":"Pivonello","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.tem.2011.09.001","article-title":"Diabetes in Cushing syndrome: basic and clinical aspects","volume":"22","author":"Mazziotti","year":"2011","journal-title":"Trends Endocrinol Metabol: TEM"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/hr.2014.111","article-title":"Increased levels of small dense low-density lipoprotein cholesterol associated with hemorheological abnormalities in untreated, early-stage essential hypertensives","volume":"37","author":"Takiwaki","year":"2014","journal-title":"Hypertension Res Off J Japan Soc Hypertension"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2011.86","article-title":"Association of hypertension with small, dense low-density lipoprotein in patients without metabolic syndrome","volume":"26","author":"Kim","year":"2012","journal-title":"J Hum Hypertension"},{"key":"B41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1161\/01.HYP.0000196306.42418.0e","article-title":"Dyslipidemia and the risk of incident hypertension in men","volume":"47","author":"Halperin","year":"2006","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn061","article-title":"Dyslipidaemia as a predictor of hypertension in middle-aged men","volume":"29","author":"Laaksonen","year":"2008","journal-title":"Eur Heart J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.0000259737.43916.42","article-title":"Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials","volume":"49","author":"Strazzullo","year":"2007","journal-title":"Hypertension (Dallas Tex 1979)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-014-3076-5","article-title":"Correlation between the severity of apnea and hypopnea sleep, hypertension and serum lipid and glycemic: a case control study","volume":"272","author":"de Sousa Rodrigues","year":"2015","journal-title":"Eur Arch Oto-rhino-laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc (EUFOS) Affiliated German Soc Oto-Rhino-Laryngol Head Neck Surg"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2016.1252055","article-title":"Markers of atherosclerosis in patients with Cushing\u2019s syndrome: a meta-analysis of literature studies","volume":"49","author":"Lupoli","year":"2017","journal-title":"Ann Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2018.02.005","article-title":"Mortality in Patients with Endogenous Cushing\u2019s Syndrome","volume":"47","author":"Javanmard","year":"2018","journal-title":"Endocrinol Metab Clinics North America"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1819-6","article-title":"Factors predicting long-term comorbidities in patients with Cushing\u2019s syndrome in remission","volume":"64","author":"Schernthaner-Reiter","year":"2019","journal-title":"Endocrine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.7326\/0003-4819-98-2-195","article-title":"Estrogen replacement therapy: indications and complications","volume":"98","author":"Judd","year":"1983","journal-title":"Ann Internal Med"},{"key":"B49","article-title":"[Hormone replacement Up-to-date. The effect of estrogen on vascular function and atherosclerosis]","volume":"17","author":"Hayashi","year":"2007","journal-title":"Clin Calcium"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-2-200007180-00010","article-title":"Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial","volume":"133","author":"Sesmilo","year":"2000","journal-title":"Ann Internal Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.600323\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T05:26:46Z","timestamp":1612848406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.600323\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":50,"alternative-id":["10.3389\/fendo.2020.600323"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.600323","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"article-number":"600323"}}